Plus Bernie wants to make hay around GLP-1 pricing. Bring it on, I say
And there's (even more) evidence that net prices are still falling.
And AEI provides some critical context for numbers on GLP-1 spending in Medicare
Amgen is suing Colorado, Maryland is moving forward, and commentary is piling up ...
And a survey of payers reveals some skepticism about CMS' price-setting prowess
And there is less than meets the eye in a new CBO presentation
And Orchard used an ICER assessment in setting the $4.25M price tag for its gene therapy
Plus a link to a great piece about discount rates, for you true wonks
Plus another 340B study shows a way the program can work to actually *help patients*
I said I'd be off, but didn't want to miss the chance to talk Pfizer, Madrigal and ... hockey hair
And Medicare coverage of weight-loss drugs is grabbing headlines following Wegovy's new approval
But there is also an IQVIA report that makes clear the cost of 340B to the average Joe
